(redirected from Phosphate binder)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.


A written document that records the essential provisions of a contract of insurance and temporarily protects the insured until an insurance company has investigated the risks to be covered, or until a formal policy is issued.

A receipt for cash or for a check that is deposited by a prospective buyer with the seller to secure the right to purchase real estate at terms that have been agreed upon by both buyer and seller.

West's Encyclopedia of American Law, edition 2. Copyright 2008 The Gale Group, Inc. All rights reserved.


n. a written statement of the key terms of an agreement, in particular insurance policies, so that the insured as well as lenders can be assured there is valid and adequate insurance coverage. (See: insurance)

Copyright © 1981-2005 by Gerald N. Hill and Kathleen T. Hill. All Right reserved.
References in periodicals archive ?
The microbial diversity showed decreasing trends in hemodialysis patients compared with healthy controls and declined further after the phosphate binder therapy [Figure 4].{Figure 4}
Floege, "Phosphate binders in chronic kidney disease: a systematic review of recent data," Journal of Nephrology, vol.
Products and formulations of commonly used phosphate binders are shown in TABLE 2.
Calcium-containing phosphate binders were used in one third of the population and vitamin D analogs in 50%.
Most patients on dialysis are currently taking many forms of phosphate binders. Clinical studies suggest that non-calcium-containing phosphate binders should be used in patients with a high risk for VC [185, 186].
Enfield et al., "Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD," Clinical Journal of the American Society of Nephrology, vol.
The education programme was established within each unit as a 12-Week Phosphate Challenge and was designed to provide patient information regarding the importance of phosphate binders and to support improved daily habits of patients relating to the taking of phosphate binders.
Phosphate binders, which inhibit the absorption of dietary phosphate, are important therapeutic tools in controlling serum P.
Weitzman, an endocrinologist at Stony Brook University, New York, examined the interaction of levothyroxine with two relatively new drugs--colesevelam (Welchol), the newest bile acid sequestrant approved for hyperlipidemia and diabetes; and lanthanum carbonate (Fosrenol), a new phosphate binder used in end-stage renal disease.